Interferon treatment of two patients with quadruple infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), hepatitis G virus (HGV), and TT virus (TTV)

Liver

Volumn 19, Issue 5, 1999, Pages 438-443

  Toyoda, Hidenori ^a   Fukuda, Yoshihide ^a,b   Yokozaki, Shoichi ^a   Nakano, Isao ^a   Hayakawa, Tetsuo ^a   Takamatsu, Junki ^b  

^a Second Dept of Internal Medicine   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatitis C virus; Hepatitis G virus; Human immunodeficiency virus; Interferon; TT virus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; DNA VIRUS; HEPATITIS; HEPATITIS C; HEPATITIS G; HEPATITIS G VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; TORQUE TENO VIRUS; VIRUS INFECTION; VIRUS TITRATION;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DNA VIRUS INFECTIONS; DNA VIRUSES; DNA, VIRAL; FLAVIVIRIDAE; HEMOPHILIA B; HEPACIVIRUS; HEPATITIS C; HEPATITIS, VIRAL, HUMAN; HIV; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; RNA, VIRAL; VIREMIA;

EID: 0032882572     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.1999.tb00075.x     Document Type: Article

References (48)

1. HOOFNAGLE J H, MULLEN K D, JONES D B, et al. Treatment of chronic non-A, non-B, hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315: 1575-8.
2. JACYNA M R, BROOKS M G, LOKE R H T, MAIN J, MURRAY-LYON I M, THOMAS H C. Randomised controlled trial of interferon alpha (lymphoblastoid interferon) in chronic non-A, non-B hepatitis. BMJ 1989; 298: 80-2.
3. DAVIS G L, BALART L A, SCHIFF E R, et al. Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter randomized controlled trial. N Engl J Med 1989; 321: 1501-6.
4. DI BISCEGLIE A M, MARTIN P, KASSIANDIES C, et al. Recombinant interferon alpha therapy for chronic hepatitis C. N Engl J Med 1989; 321: 1506-10.
5. SHINDO M, DI BISCEGLIE A, CHEUNG L, et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991; 115: 700-4.
6. CHAYAMA K, SAITOH S, ARASE Y, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991; 13: 1040-3.
7. HAGIWARA H, HAYASHI N, MITA E, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha. Hepatology 1992; 15: 37-41.
8. LANE H C, DAVEY V, KOVACS J A, et al. Interferon-α in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med 1990; 112: 805-11.
9. KROWN S E, GOLD J W M, NIEDZWIECKI D, et al. Interferon-α with zidovudine: safety, tolerance, and clinical and virologie effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 112: 812-21.
10. BOYER N, MARCELLIN P, DEGOTT C, et al. Recombinant interferon-α for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis 1992; 165: 723-6.
11. MARRIOTT E, NAVAS S, DEL ROMERO J, et al. Treatment with recombinant α-interferon of chronic hepatitis C in anti-HIV-positive patients. J Med Virol 1993; 40: 107-11.
12. SORIANO V, GARCIA-SAMANIEGO J, BRAVO R, et al. Efficacy and safety of α-interferon treatment for chronic hepatitis C in HIV-infected patients. J Infect 1995; 31: 9-13.
13. SORIANO V, GARCIA-SAMANIEGO J, BRAVO R, et al. Interferon α for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 23: 585-91.
14. MAUSS S, KLINKER H, ULMER A, et al. Response to treatment of chronic hepatitis C with interferon a in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection 1998; 26: 16-9.
15. SIMONS J N, LEARY T P, DAWSON G J, et al. Isolation of novel virus-like sequences associated with human hepatitis. Nat Med 1995; 1: 564-9.
16. LINNEN J, WAGES JR J, ZHANG-KECK Z-Y, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996; 271: 505-8.
17. BERG T, DIRLA U, NAUMANN U, et al. Responsiveness to interferon alpha treatment in patients with chronic hepatitis C coinfected with hepatitis G virus. J Hepatol 1996; 25: 763-8.
18. CHEUNG R C, KEEFE E B. Hepatitis G virus: clinical relevance and responsiveness to interferon. Am J Gastroenterol 1997; 92: 1957-9.
19. INOUE T, SAKAMOTO M, AKAHANE Y, OKAMOTO H, MIYAKAWA Y, MAYUMI M. Response to interferon of GB virus C and hepatitis C virus in patients with chronic hepatitis. Am J Gastroenterol 1997; 92: 1981-5.
20. UMLAUFT F, WONG D T, UNDERHILL P A, et al. Hepatitis G virus infection in hemodialysis patients and the effects of interferon treatment. Am J Gastroenterol 1997; 92: 1986-91.
21. NAGAYAMA R, MIYAKE K, OKAMOTO H. Effect of interferon on GB virus C and hepatitis C virus in hepatitis patients with the co-infection. J Med Virol 1997; 52: 156-60.
22. ORITO E, MIZOKAMI M, YASUDA K, et al. Interferon-α therapy in patients dually infected with hepatitis C virus and GB virus C/hepatitis G virus-virological response of HGV and pretreatment HGV viremia level. J Hepatol 1997; 27: 603-12.
23. MCHUTCHISON J G, NAINAN O V, ALTER M J, et al. Hepatitis C and G co-infection: response to interferon therapy and quantitative changes in serum HGV-RNA. Hepatology 1997; 26: 1322-7.
24. NISHIZAWA T, OKAMOTO H, KONISHI K, YOSHIZAWA H, MIYAKAWA Y, MAYUMI M. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun 1997; 241: 92-7.
25. OKAMOTO H, NISHIZAWA T, KATO N, et al. Molecular cloning and characterization of a novel DNA virus (TTV) associated with posttransfusion hepatitis of unknown etiology. Hepatol Res 1998; 10: 1-16.
26. DESMET V J, GERBER M, HOOFNAGLE J H, MANNS M, SCHEUER P J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
27. OKAMOTO H, OKADA S, SUGIYAMA Y, et al. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med 1990; 60: 215-22.
28. SIMMONDS P, ALBERTI A, ALTER H J, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-4.
29. OKAMOTO H, KOBATA S, TOKITA H, et al. A second-generation method of genotyping hepatitis C virus by the polymerase chain reaction with sense and antisense primers deduced from the core gene. J Virol Methods 1996; 57: 31-45.
30. SHIMIZU M, OSADA K, OKAMOTO H. Transfusion-transmitted hepatitis G virus following open heart surgery. Transfusion 1996; 36: 937.
31. TOYODA H, FUKUDA Y, HAYAKAWA T, TAKAMATSU J, SAITO H, OKAMOTO H. GB virus C/hepatitis G virus isolates in Japanese haemophiliacs and their origins. Thromb Haemost 1998; 80: 242-5.
32. MUERHOFF A S, SIMONS J N, LEARY T P, et al. Sequence heterogeneity within the 5′-terminal region of the hepatitis GB virus C genome and evidence for genotypes. J Hepatol 1996; 25: 379-84.
33. TAKAHASHI K, HOSHINO H, OHTA Y, YOSHIDA N, MISHIRO S. Very high prevalence of TT virus (TTV) infection in general population of Japan revealed by a new set of PCR primers. Hepatol Res 1998; 12: 233-9.
34. DETMER J, LAGIER R, FLYNN J, et al. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J Clin Microbiol 1996; 34: 901-7.
35. HEID C A, STEVENS J, LIVAK K J, WILLIAMS P M. Real time quantitative PCR. Genome Res 1996; 6: 986-94.
36. VENTO S, DI PERRI G, CRUCIANI M, GAROFANO T, CONCIA E, BASSETTI D. Rapid decline of CD4+ cells after IFN-α treatment in HIV-1 infected. Lancet 1993; 341: 958-9.
37. PESCE A, TAILLAN B, ROSENTHAL E, et al. Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients. Lancet 1993; 341: 1597.
38. SIMMONDS P, DAVIDSON F, LYCETT C, et al. Detection of a novel virus (TTV) in blood donors and blood products. Lancet 1998; 352: 191-5.
39. BISSUEL F, TRABAUD M-A, LERICHE K, et al. Tolerance of a triple combination therapy with zidovudine, didanosine and interferon in seven HIV-infected patients. AIDS 1995; 9: 1285.
40. LAU J Y N, DAVIS G L, KNIFFEN J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-4.
41. HAGIWARA H, HAYASHI N, MITA E, et al. Quantitative analysis of hepatitis C virus in serum dunug interferon alpha therapy. Gastroenterology 1993; 104: 877-83.
42. TOYODA H, NAKANO S, KUMADA T, et al. Comparison of serum hepatitis C virus RNA concentration measurement by branched DNA probe assay with competitive polymerase chain reaction as a predictor of response to interferon-α therapy in chronic hepatitis C patients. J Med Virol 1996; 48: 354-9.
43. YOSHIOKA K, KAKUMU S, WAKITA T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon alfa therapy: relation to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-9.
44. TSUBOTA A, CHAYAMA K, IKEDA K, et al. Factors predictive of response to interferon-a therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-94.
45. SORIANO V, GARCIA-LERMA G, BRAVO R, et al. Lack of antiretroviral effect of alpha-interferon in HIV-infected patients treated for chronic hepatitis C. J Infect 1997; 35: 319-20.
46. EDLIN B R, ST CLAIR M H, PITHA P M, et al. In vitro resistance to ZDV and alpha-interferon in HIV-1 isolates from patients: correlation with treatment duration and response. Ann Intern Med 1992; 117: 457-60.
47. BROOK M, GOR D, FORSTER S, HARRIS W, JEFFRIES D, THOMAS H. Suppression of HIV p24 antigen and induction of HIV anti-p24 antibody by alpha interferon in patients with chronic hepatitis B. AIDS 1988; 2: 391-3.
48. ORHOLM M, PEDERSEN C, MATHIESEN L, DOWD P, NIELSEN J. Suppression of p24 antigen in sera from HIV-infected individuals with low-dose alpha-interferon and zidovudine: a pilot study. AIDS 1989; 3: 97-100.